Researchers at the University of Texas MD Anderson Cancer Center have identified a blood-based biomarker that may help identify patients with glioblastoma who are most likely to achieve long-term survival from novel treatment with an engineered oncolytic virus, delta-24-RGD, that targets and eliminates cancer cells.
Please follow and like us:
